We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Joint Arthroplasty Market Surges, Despite Recessionary Pressures

By HospiMedica International staff writers
Posted on 14 Oct 2009
Novel technology is driving growth in the joint arthroplasty and fixation bone-cement market in industrialized countries, while increased disposable income is creating new markets in emerging economies. More...
These are the latest findings of the Millennium Research Group (MRG, Toronto, Canada), a medical technology market intelligence, and strategic information company.

While recessionary pressures slowed growth in joint arthroplasty procedures between 2008 and 2009, patients and surgeons are driving demand for elective orthopedic procedures, with novel technologies, such as hip resurfacing and joint revision implants, enabling a wider range of patients to be treated in the United States, Europe, and Japan, while the burgeoning middle classes in Brazil, China, and India are opting for elective joint replacement procedures and driving global growth by an expected 7% annual growth rate through 2013.

In the United States and Europe, a two-stage revision procedure has become the standard of care for treating infected hip and knee arthroplasty. Silicone-based cement spacer molds allow the surgeon to create an antibiotic cement implant in the shape of a prosthetic hip or knee implant. This antibiotic-loaded implant preserves normal leg length, allows for early patient mobilization, and quickly delivers the antibiotics locally to the periprosthetic space to prevent further infection.

"Although cement spacer molds are gaining surgeon acceptance, the relatively high device price can be prohibitive, particularly in facilities with restricted budgets and in countries where patients pay for the vast majority of medical expenses out-of-pocket,” said MRG analyst Melissa Hussey. "As of 2009, China and India had not approved the use of cement spacer molds, and their adoption has been limited in Brazil due to the additional cost they add to the procedure. Globally, however, the market for cement spacer molds will grow considerably over the next five years.”

MRG expects that as device benefits emerge, their adoption will increase in all countries under study. The resulting procedure volume growth will propel sales of bone cement, cement mixing and delivery systems, and cement spacer molds. The prefabricated cement spacer-mold segment is expected to outperform the overall market, with 10% annual growth rate fueled by the release of positive clinical data for this relatively new technology.

Related Links:

Millennium Research Group



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.